Lion’s mane is unique among all functional mushrooms for one reason: it is the only mushroom in which two key classes of bioactive compounds are split between the fruiting body and the mycelium.
Hericenones are aromatic, lipophilic compounds present in the fruiting body. Erinacines are diterpenoids, present mainly in the mycelium and also measurable in the fruiting body; it is precisely their molecular structure that the work of Rupcic and colleagues in the “International Journal of Molecular Sciences” (2018) addresses, in which two new cyathane diterpenoids from Hericium erinaceus were chemically isolated and structurally described.
In addition, the fruiting body contains β-1,3/1,6-glucans (polysaccharides), ergothioneine (an antioxidant) and ergosterol, provitamin D₂. This is a fuller profile of the mushroom, not a single isolated molecule.
The state of knowledge about lion’s mane rests on studies of varying levels of evidence, which must be told apart from one another. Some concern cell cultures and animal models, for example studies on nerve growth factor (NGF). These are preliminary studies, conducted mainly on cells and animals, not a diagnosis or a promise of an effect in humans.
There are also a few studies with human participants: a double-blind, randomised study (Mori 2009, n=30 people with mild cognitive impairment, 16 weeks, 3 g a day) described higher HDS-R scores in the group taking lion’s mane at weeks 8, 12 and 16, with the effect fading 4 weeks after discontinuation. A pilot study (Docherty 2023, n=41 healthy adults, 28 days, 1.8 g a day) described a shorter Stroop-test completion time after a single dose (p=0.005) and lower subjective stress after 28 days.
These are preliminary studies, on small groups. They suggest directions for observation, they do not prove an effect and they are not the basis for any health claim about the product.
Let us be honest: these are studies of the raw material, its molecules and preliminary observations, most often conducted in the laboratory, not of our supplement. Our raw material is standardised to a minimum of 30% β-glucans, measured by the Megazyme method, and we control the hericenone and erinacine profile descriptively by HPLC, according to the batch. Standardising the composition is, for us, a reason to care about extract quality, not a basis for health promises. Bibliographic data: PubMed.
The cited papers concern the raw material and its compounds, not our product. They are not claims about treatment.